Nov 8, 2024 · Grade 3 rash (confluent rash with fever, generalized rash) occurred in 2 patients, and grade 4 rash (erythema multiforme) occurred in 4 patients. The median time to onset of rash in pediatric patients was 28 days.

A mild-to-moderate maculopapular rash occurs in 2 – 10% of patients, usually within the first few weeks and resolving within a month without discontinuing therapy. Severe skin rash is rare, and efavirenz should be discontinued if it occurs.

Jul 2, 2024 · Efavirenz/emtricitabine/tenofovir DF can cause serious, life-threatening side effects. These include a buildup of lactic acid in the blood (lactic acidosis), liver problems, severe skin rash and allergic reactions, mental health problems, and new or worsening kidney problems, including kidney failure.

Dec 28, 2023 · Rashes are usually mild-to-moderate maculopapular skin eruptions that occur within the first 2 weeks of initiating therapy with EFV (median time to onset of rash in adults was 11 days) and, in most subjects continuing therapy with EFV, rash resolves within 1 month (median duration, 16 days).

Nov 12, 2024 · Get emergency medical help if you have signs of an allergic reaction (hives, difficult breathing, swelling in your face or throat) or a severe skin reaction (fever, sore throat, burning eyes, skin pain, red or purple skin rash with blistering and peeling). Efavirenz may cause serious side effects. Call your doctor at once if you have:

Nov 2, 2021 · Rashes are usually mild-to-moderate maculopapular skin eruptions that occur within the first 2 weeks of initiating therapy with EFV (median time to onset of rash in adults was 11 days) and, in most patients continuing therapy with EFV, rash resolves within 1 month (median duration, 16 days).

The incidence of Grade 4 rash (e.g., erythema multiforme, Stevens-Johnson syndrome) in adult subjects treated with EFV in all trials and expanded access was 0.1%. Rashes are usually...

Skin rash is the most frequently observed adverse event associated with NVP, manifesting as a diffuse maculopapular rash or erythema-tous rash with or without constitutional symptoms. The risk of rash of any severity is greatest in the first 6 weeks of treatment [10]. Generally, the rash is mild and transient.

Jun 27, 2024 · Rashes are usually mild-to-moderate maculopapular skin eruptions that occur within the first 2 weeks of initiating therapy with EFV (median time to onset of rash in adults was 11 days) and, in most subjects continuing therapy with EFV, rash resolves within 1 month (median duration, 16 days).

Objectives: We aimed to determine the incidence and predictors of nevirapine and efavirenz-associated rash among Indo-nesian HIV-infected patients. Methods: A retrospective cohort study was conducted among Indonesian patients who were using nevirapine or efavirenz between January 2004 to December 2013.